Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Thoracic 2Sarcoma 2Gastrointestinal 2CNS 2Breast 2

Conditions

Recurrence 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × 1-methyltryptophan × Thoracic × Clear all
NCT02460367 2022-04-06

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Lumos Pharma

Phase 1 Terminated
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT00739609 2020-05-28

D-1MT

Lumos Pharma

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡